HCV Drugs

Medical Advocates
HCV Infection/Disease

Interferon Therapy

General Reports
Consensus Interferon
Interferon Alpha
Recombinant Interferon-Alpha
Interferon Alpha/RBV
Interferon Alpha-2a
Interferon Alpha-2b
Interferon Alpha-2a/RBV
Interferon Alpha-2b/RBV
Interferon Alpha-2b/RBV/AMT
Interferon Beta
Albinterferon-alfa 2b Peg Interferon-Alfa-2a
Peg Interferon-Alfa-2b

HCV Drugs Main Page

Main New/Newsworthy

Home Page

Last Update: October 11, 2011
Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader

General Reports

Journal Papers, Abstracts, and Commentaries

Ophthalmological complications in hepatitis C virus infection: Side effect of interferon therapy
or a direct role of HCV?
Pazienza V.
Biomed Pharmacother. 2011 May 30
Abstract

FULL-TEXT ARTICLE
Difficulties with interferon treatment in former intravenous drug users.
Gazdag G, Horváth G, Szabó O, Ungvari GS.
Braz J Infect Dis. 2011 Apr;15(2):163-6.
Paper

Does interferon therapy prevent hepatocellular carcinoma in patients with chronic viral hepatitis?
Vezali E, Aghemo A, Lampertico P, Colombo M.
Clin Res Hepatol Gastroenterol. 2011 Mar 22.17;7(1):192
Abstract

Dental problems delaying the initiation of interferon therapy for HCV-infected patients.
Nagao Y, Sata M.
Virol J. 2010 Aug 17;7(1):192
Abstract

Meta-analysis of factors associated with sustained viral response in patients on
hemodialysis treated with standard or pegylated interferon for hepatitis C infection.
Alavian SM, Tabatabaei SV.
Iran J Kidney Dis. 2010 Jul;4(3):181-94.
Abstract

Hepatitis: Treatment of chronic hepatitis C-how much interferon is enough?
Ferenci P.
Nat Rev Gastroenterol Hepatol. 2010 Apr;7(4):191-3
Abstract

Interferon therapy of hepatitis C: molecular insights into success and failure.
Sarasin-Filipowicz M.
Swiss Med Wkly. 2009 Nov 30.
Abstract

Hepatitis C: The role of new interferons in the era of STAT-C.
Moucari R, Marcellin P.
Nat Rev Gastroenterol Hepatol. 2009 Sep;6(9):509-11
Abstract

Long-term Outcomes After Treatment With Interferon and Ribavirin in HCV Patients.
Aronsohn A, Reau N.
J Clin Gastroenterol. 2009 May 14
Abstract

Analysis of factors interfering with the acceptance of interferon therapy by HCV-infected patients.
Nagao Y, Kawakami Y, Yoshiyama T, Sata M.
Med Sci Monit. 2008 Nov;14(11):PI45-52.
Abstract

Eradication of Hepatitis C Virus in Patients Successfully Treated for Chronic Hepatitis C.
Maylin S, Martinot-Peignoux M, Moucari R, et al
Gastroenterology. 2008 May 21.
Abstract

Prediction of virologic response in difficult-to-treat chronic hepatitis C patients during high-dose
interferon induction therapy.
Gelderblom HC, Zaaijer HL, Dijkgraaf MG, et al
Scand J Gastroenterol. 2008;43(7):857-69.
Abstract

nterferon signaling and treatment outcome in chronic hepatitis C.
Sarasin-Filipowicz M, Oakeley EJ, Duong FH, et al
Proc Natl Acad Sci U S A. 2008 May 8
Abstract

Treatment of chronic hepatitis C in haemophilic patients with interferon and ribavirin: a meta-analysis.
Franchini M, Mengoli C, Veneri D,et al
J Antimicrob Chemother. 2008 Mar 19
Abstract

Eicosapentaenoic Acid Could Permit Maintenance of the Original Ribavirin Dose in Chronic
Hepatitis C Virus Patients during the First 12 Weeks of Combination Therapy with
Pegylated Interferon-alpha and Ribavirin. A Prospective Randomized Controlled Trial.
Takaki S, Kawakami Y, Imamura M, Aikata
Intervirology. 2008 Feb 4;50(6):439-446 [
Abstract

Effect of sustained virological response to treatment on the incidence of abnormal glucose
values in chronic hepatitis C.
Romero-Gómez M, Fernández-Rodríguez CM, Andrade RJ, et al
J Hepatol. 2008 Jan 15
Abstract

Hepatitis C virus and the controversial role of the interferon sensitivity determining region
in the response to interferon treatment.
Torres-Puente M, Cuevas JM, Jiménez-Hernández N, et al
J Med Virol. 2008 Feb;80(2):247-53.
Abstract

Intravenous interferon during the anhepatic phase of liver retransplantation and prevention of
recurrence of cholestatic hepatitis C virus.
Kwo PY, Saxena R, Cummings OW, Tector AJ.
Liver Transpl. 2007 Nov 28;13(12):1710-1713
Abstract

Interferon-based therapy of hepatitis C.
Chevaliez S, Pawlotsky JM.
Adv Drug Deliv Rev. 2007 Aug 11;
Abstract

Trend of Depression and the Use of Psychiatric Medications in U.S. Veterans With
Hepatitis C During Interferon-Based Therapy.
Jakiche A, Paredez EC, Tannan PK, et al
Am J Gastroenterol. 2007 Jul 19;
Abstract

Interferon-based treatment of chronic hepatitis C.
Souvignet C, Lejeune O, Trepo C.
Biochimie. 2007 May 8;
Abstract

FULL TEXT ARTICLE
The interferon inducing pathways and the hepatitis C virus.
Meurs EF, Breiman A.
World J Gastroenterol. 2007 May 7;13(17):2446-54.
Paper

Hepatocellular carcinoma occurring after 11 year-long sustained viral response to interferon
therapy for chronic hepatitis C.
Suganami F, Tomiyama Y, Ohmoto K, et al
Nippon Shokakibyo Gakkai Zasshi. 2007 Jun;104(6):809-14.
Abstract

Pretreatment preparation and management of interferon-based therapy for hepatitis C virus
infection.
Hopwood M, Treloar C.
J Adv Nurs. 2007 May 25
Abstract

Sustained virological response to interferon reduces cirrhosis in chronic hepatitis C:
a 1386-patient study from Taiwan.
Huang JF, Yu ML, Lee CM, et al
Aliment Pharmacol Ther. 2007 May;25(9):1029-37
Abstract

Utility of week-4 viral response to tailor treatment duration in hepatitis C virus genotype
3/HIV co-infected patients.
Crespo M, Esteban JI, Ribera E, et al
AIDS. 2007 Feb 19;21(4):477-481.
Abstract

Interferon Therapy Improves the Irregular Regeneration of Hepatocytes in Liver in Patients
with C-Viral Chronic Hepatitis and Liver Cirrhosis.
Moriyama M, Matsumura H, Oshiro S, et al
Intervirology. 2006 Dec 22;50(2):138-149
Abstract

Consensus Interferon

Journal Papers, Abstracts, and Commentaries

Retreatment of Hepatitis C with Consensus Interferon and Ribavirin After Nonresponse or Relapse to
Pegylated Interferon and Ribavirin: A National VA Clinical Practice Study.
Yee HS, Currie SL, Tortorice K, et al
Dig Dis Sci. 2011 Jun
Abstract

A WEEK-IN-REVIEW FEATURED REPORT
U.S. Multicenter Pilot Study of Daily Consensus Interferon (CIFN) Plus Ribavirin for "Difficult-to-Treat" HCV
Genotype 1 Patients.
Ho SB, Aqel B, Dieperink E, et al
Dig Dis Sci. 2011 Jan 11
Abstract

Comparative efficacy and overall safety of different doses of consensus interferon for
treatment of chronic HCV infection: a systematic review and meta-analysis.
Alavian SM, Behnava B, Tabatabaei SV.
Eur J Clin Pharmacol. 2010 Sep 21.
Abstract

FULL-TEXT ARTICLE
Management of chronic hepatitis C treatment failures: role of consensus interferon.
Gonzalez SA, Keeffe EB.
Biologics. 2009;3:141-50.
Paper

FULL TEXT PDF ARTICLE
Systemic sclerosis after interferon alphacon-1 therapy for hepatitis C.
Tahara H, Kojima A, Hirokawa T, et al
Intern Med. 2007;46(8):473-6.
Paper

FULL-TEXT ARTICLE
Randomized controlled trial of consensus interferon with or without zinc for chronic hepatitis C
patients with genotype 2.
Suzuki H, Sato K, Takagi H, et al
World J Gastroenterol. 2006 Feb 14;12(6):945-50
Paper

Consensus interferon for chronic hepatitis C patients with genotype 1 who failed to respond to,
or relapsed after, interferon alpha-2b and ribavirin in combination: an Italian pilot study.
Barbaro G, Barbarini G.
Eur J Gastroenterol Hepatol 2002 May;14(5):477-83
Abstract

Interferon Alpha

General Reports

Journal Papers, Abstracts, and Commentaries

Comparison of Immune Restoration in Early versus Late Interferon Alpha
Therapy against Hepatitis C Virus.
Abdel-Hakeem MS, Bédard N, Badr G, et al
J Virol. 2010 Jul 28
Abstract

Interferon-alpha-induced TRAIL on natural killer cells is associated with control of hepatitis
C virus infection.
Stegmann KA, Björkström NK, Veber H, et al
Gastroenterology. 2010 May;138(5):1885-97
Abstract

Efficacy of interferon plus ribavirin in the treatment of hepatitis C virus genotype 5.
Antaki N, Hermes A, Hadad M, et al
J Viral Hepat. 2008 May;15(5):383-6.
Abstract

Musculoskeletal complaints and serum autoantibodies associated with chronic hepatitis C and
nonalcoholic Fatty liver disease.
Banks SE, Riley Iii TR, Naides SJ.
Dig Dis Sci. 2007 May;52(5):1177-82.
Abstract

Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of mild chronic
hepatitis C: a systematic review and economic evaluation.
Shepherd J, Jones J, Hartwell D, et al
Health Technol Assess. 2007 Mar;11(11):1-224
Abstract

FULL TEXT ARTICLE
Interferon alpha therapy for hepatitis C: treatment completion and response rates among
patients with substance use disorders.
Huckans MS, Loftis JM, Blackwell AD
Subst Abuse Treat Prev Policy. 2007 Jan 12;2:4.
Paper

Dermatologic Disorders Associated With Chronic Hepatitis C: Effect of Interferon Therapy.
Berk DR, Mallory SB, Keeffe EB, Ahmed A
Clin Gastroenterol Hepatol. 2006 Aug 16;
Abstract

Treatment of interferon-alpha for chronic hepatitis C.
Moriyama M, Arakawa Y.
Expert Opin Pharmacother. 2006 Jun;7(9):1163-79.
Abstract

Efficacy of Interferon-alpha in the Treatment of Chronic Hepatitis C in Dialysis Patients:
Two Therapeutic Protocols Compared.
Grgurevic I, Vince A, Buljevac M, et al
Nephron Clin Pract. 2005 Dec 21;103(1):c8-c11
Abstract

Acquired factor VIII inhibitor in patients with hepatitis C virus infection and the role of
interferon-alpha: A case report.
Schreiber ZA, Brau N.
Am J Hematol. 2005 Nov 28;80(4):295-298
Abstract

FULL-TEXT PDF ARTICLE
High versus standard doses interferon-alpha in the treatment of naive chronic hepatitis C patients
in Taiwan: a 10-year cohort study
Ming-Lung Yu M-L, Chia-Yen Dai C-Y, et al
BMC Infectious Diseases 2005, 5:27
Paper

Favorable prognosis of chronic hepatitis C after interferon therapy by long-term cohort study.
Imazeki F, Yokosuka O, Fukai K, Saisho H.
Hepatology. 2003 Aug;38(2):493-502.
Abstract

Adverse Events

Journal Papers, Abstracts, and Commentaries

Irreversible Pulmonary Hypertension Associated with the use of Interferon Alpha
for Chronic Hepatitis C.
Dhillon S, Kaker A, Dosanjh A, et AL
Dig Dis Sci. 2010 Apr 22.
Abstract

Psychiatric problems in patients infected with hepatitis C before and during antiviral treatment
with interferon-alpha: a review.
Quelhas R, Lopes A.
J Psychiatr Pract. 2009 Jul;15(4):262-81
Abstract

Subthreshold mania as predictor of depression during interferon treatment in HCV(+)
patients without current or lifetime psychiatric disorders.
Dell'osso L, Pini S, Maggi L
J Psychosom Res. 2007 Mar;62(3):349-55.
Abstract

Rejection under alpha interferon therapy in liver transplant recipients.
Walter T, Dumortier J, Guillaud O, et al
Am J Transplant. 2007 Jan;7(1):177-84
Abstract

Sarcoidosis after treatment with interferon-alpha: A case series and review of the literature.
Goldberg HJ, Fiedler D, Webb A
Respir Med. 2006 May 2;
Abstract

Sarcoidosis caused by interferon therapy.
Celik G, Sen E, Ulger AF, Kumbasar OO,
Respirology. 2005 Sep;10(4):535-40.
Abstract

Prevention of interferon-alpha associated depression in psychiatric risk patients with
chronic hepatitis C.
Schaefer M, Schwaiger M, Garkisch AS, et al
J Hepatol. 2005 Jun;42(6):793-8.
Abstract

Uterine Sarcoidosis Potentially Associated With Interferon-{alpha} Use for Chronic Hepatitis C
Infection.
Tsiodras S, Drimala P, Stavreas N, et al
Obstet Gynecol. 2005 May;105(5):1198-201
Abstract

Is Steroid Therapy Needed in the Treatment of Destructive Thyrotoxicosis Induced by
alpha-Interferon in Chronic Hepatitis C?
Minelli R, Valli MA, Di Secli C, et al|
Horm Res. 2005 Apr 28;63(4):194-199
Abstract

Major depressive disorder with psychotic features induced by interferon-{alpha} treatment
for hepatitis C in a polydrug abuser.
Kalyoncu OA, Tan D, Mirsal H, et al
J Psychopharmacol. 2005 Jan;19(1):102-5.
Abstract

Recombinant Interferon Alpha

Journal Papers, Abstracts, and Commentaries

Chronic hepatitis C infection and sex hormone levels: effect of disease severity and recombinant
interferon-alpha therapy.
Nguyen HV, Mollison LC, Taylor TW, et al
Intern Med J. 2006 Jun;36(6):362-6.
Paper

Interferon Alpha 2a

Interferon Alpha-2a/RBV

Journal Papers, Abstracts, and Commentaries

Treatment profile of hepatitis C patients - a comparison of interferon alpha 2a
and 2b treatment regimes.
Aziz S, Qamar R, Ahmed I, et al
J Coll Physicians Surg Pak. 2010 Sep;20(9):581-5.
Abstract

Peripheral neuropathy during a second cycle of treatment with high doses of
interferon alpha in a patient with hepatitis C, and a review of the literature
Tellez Zenteno JF, Negrete Pulido O, et al.
Rev Neurol 2002 Oct 1;35(7):644-6
Abstract

FULL-TEXT ARTICLE
Interferon alfa with or without ribavirin for chronic hepatitis C: systematic review of
randomised trials.
Kjaergard LL, Krogsgaard K, Gluud C.
BMJ 2001 Nov 17;323(7322):1151-5
Paper

Interferon Alpha 2b

Interferon Alpha-2b/RBV

Journal Papers, Abstracts, and Commentaries

Two week induction of interferon-beta followed by pegylated interferon alpha-2b
and ribavirin for chronic infection with hepatitis C.
Matsui K, Iwabuchi S, Shimizu H, et al
Hepatol Res. 2010 Jun 8
Abstract

FULL-TEXT PDF ARTICLE
Exacerbation of hepatitis C induced subclinical hypoadrenalism by interferon-alpha2beta:
a case report.
Tran HA, Song S, Lojewski RJ, Reeves GE.
Cases J. 2008 Sep 18;1(1):157
Paper

A WEEK-IN-REVIEW FEATURED REPORT
Interferon alfa-2b continuous long-term therapy versus repeated 24-week cycles for retreating
chronic Hepatitis C.
McHutchison JG, Patel K, Schiff ER, et al
Aliment Pharmacol Ther. 2007 Dec 11
Abstract

Treatment of Early Diagnosed HCV Infection in Hemodialyzed Patients with Interferon-alpha.
Treatment of Hepatitis C.
Urbanek P, Tesar V, Prochazkova-Francisci E, et al
Blood Purif. 2004 Jul 16;22(4):344-350.
Abstract

Pretreatment hepatitis C virus dynamics for predicting virological response to
interferon-alpha2b monotherapy in patients with chronic hepatitis C virus infection.
Sainokami S, Abe K, Suzuki K, Ishikawa K. et al
Hepatol Res. 2003 Nov;27(3):181-191.
Abstract

Antiviral treatment in acute hepatitis C.
Macedo G, Correia A, Ribeiro T.
Hepatogastroenterology. 2003 Jul-Aug;50(52):1057-9.
Abstract

Daily or three times per week interferon alpha-2b in combination with ribavirin or
interferon alone for the treatment of patients with chronic hepatitis C not responding
to previous interferon alone.
de Ledinghen V, Trimoulet P, Winnock M, et al.
J Hepatol 2002 Jun;36(6):819-26
Abstract

Efficacy of daily induction dosing vs standard thrice weekly dosing of interferon-alpha2B
for initial treatment of chronic hepatitis C.
Gonzalez HJ, Ho SB, Gross JB. et al.
Dig Dis Sci 2002 Apr;47(4):784-92
Abstract

A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected
patients awaiting liver transplantation.
Crippin JS, McCashland T, Terrault N, et al
Liver Transpl 2002 Apr;8(4):350-5
Abstract

FULL-TEXT ARTICLE
Changes in anti-viral effectiveness of interferon after dose reduction in chronic hepatitis c
patients: a case control study.
Bekkering FC, Neumann AU, Brouwer JT, et al.
BMC Gastroenterol 2001;1(1):14
Paper

A randomized trial of high-dose interferon alpha-2b, with or without ribavirin, in chronic
hepatitis C patients who have not responded to standard dose interferon.
Malik AH, Kumar KS, Malet PF, et al
Aliment Pharmacol Ther 2002 Mar;16(3):381-8
Abstract

Treatment of acute hepatitis C with interferon alfa-2b.
Jaeckel E, Cornbeg M, Wedemeyer H, et al.
N Engl J Med 2001 Nov 15;345(20):1452-7
Abstract

Interferon alpha/Ribavirin

Journal Papers, Abstracts, and Commentaries

Efficacy of chronic hepatitis C therapy with pegylated interferon and ribavirin in patients on methadone maintenance |
treatment.
Neukam K, Mira JA, Gilabert I, et al
Eur J Clin Microbiol Infect Dis. 2011 Oct 6
Abstract
Changes in Depressive Symptoms and Impact on Treatment Course Among Hepatitis C Patients
Undergoing Interferon-α and Ribavirin Therapy: A Prospective Evaluation.
Chapman J, Oser M, Hockemeyer J, et al
Am J Gastroenterol. 2011 Aug 9.
Abstract

Sexual Dysfunction in Chronic Hepatitis C Virus Patients Treated with Interferon Alpha and Ribavirin.
Malaguarnera M, Vicari E, Calogero A,
J Interferon Cytokine Res. 2008 Sep 8.
Abstract

Sustained response to interferon-alpha plus ribavirin therapy for chronic hepatitis C is closely
associated with increased dynamism of intrahepatic natural killer and natural killer T cells.
Yamagiwa S, Matsuda Y, Ichida T, et al
Hepatol Res. 2008 Mar 4
Abstract

Fulminant central nervous system demyelination associated with interferon-{alpha} therapy and
hepatitis C virus infection.
Höftberger R, Garzuly F, Dienes HP,et a
Mult Scler. 2007 Nov;13(9):1100-6.
Abstract

FULL TEXT ARTICLE
Effect of sustained virological response on long-term clinical outcome in 113 patients with
compensated hepatitis C-related cirrhosis treated by interferon alpha and ribavirin.
Braks RE, Ganne-Carrie N, Fontaine H., et al
World J Gastroenterol. 2007 Nov 14;13(42):5648-53
Paper

A WEEK-IN-REVIEW FEATURED REPORT
Intraocular complications of IFN-alpha and ribavirin therapy in patients with chronic viral
hepatitis C.
Sene D, Touitou V, Bodaghi B, et al
World J Gastroenterol. 2007 Jun 14;13(22):3137-3140.
Abstract

FULL-TEXT ARTICLE
Interferon alpha plus ribavirin combination treatment of Japanese chronic hepatitis C patients
with HCV genotype 2: A project of the Kyushu University Liver Disease Study Group.
Furusyo N, Katoh M, Tanabe Y, et al
World J Gastroenterol. 2006 Feb 7;12(5):784-90.
Paper

A WEEK-IN-REVIEW FEATURED REPORT
Effects of Adding Ribavirin to Interferon to Treat Chronic Hepatitis C Infection: A Systematic
Review and Meta-analysis of Randomized Trials.
Brok J, Gluud LL, Gluud C.
Arch Intern Med. 2005 Oct 24;165(19):2206-12.
Abstract

A WEEK-IN-REVIEW FEATURED REPORT
Limitation of combination therapy of interferon and ribavirin for older patients with chronic hepatitis C.
Iwasaki Y, Ikeda H, Araki Y, et al
Hepatology. 2006 Jan;43(1):54-63.
Abstract

Depressive symptoms and viral clearance in patients receiving interferon-alpha and ribavirin
for hepatitis C.
Raison CL, Broadwell SD, Borisov AS, et al
Brain Behav Immun. 2005 Jan;19(1):23-7.
Abstract

Retinopathy-associated alpha-interferon-ribavirin therapy and the importance of the electro-
oculogram: a case report
Crochet M, Ingster-Moati I, Even G, Dupuy P.
J Fr Ophtalmol. 2004 Mar;27(3):257-62.
Abstract

Interferon plus ribavirin in patients with hepatitis C virus positive mixed cryoglobulinemia
resistant to interferon.
Mazzaro C, Zorat F, Comar C, et al
J Rheumatol. 2003 Aug;30(8):1775-81.
Abstract

Interferon alpha-2a/Ribavirin

Journal Papers, Abstracts, and Commentaries

Effect of an induction period of pegylated interferon-α2a and ribavirin on early virological response in HIV-HCV-coinfected patients: results from the CORAL-2 study.
Tural C, Solà R, Alvarez NP, et al
Antivir Ther. 2011;16(6):833-841
Abstract

A case of peripheral facial nerve palsy with cryoglobulinemia and chronic thyroiditis occurring
during interferon plus ribavirin therapy for chronic hepatitis C.
Sumida Y, Kanemasa K, Fukumoto K, et al
Nippon Shokakibyo Gakkai Zasshi. 2007 Jun;104(6):815-21
Abstract

Diabetes mellitus reduces the therapeutic effectiveness of interferon-alpha2b plus ribavirin
therapy in patients with chronic hepatitis C.
Konishi I, Horiike N, Hiasa Y
Hepatol Res. 2007 May;37(5):331-6
Abstract

FULL-TEXT ARTICLE
Effect of interferon alpha and ribavirin treatment on serum levels of transforming growth factor-beta1,
vascular endothelial growth factor, and basic fibroblast growth factor in patients with chronic hepatitis C.
Janczewska-Kazek E, Marek B, et al
World J Gastroenterol. 2006 Feb 14;12(6):961-5.
Paper

Thyroid dysfunction in patients with chronic hepatitis C receiving a combined therapy of interferon and
ribavirin: Incidence, associated factors and prognosis.
Kee KM, Lee CM, Wang JH, Tung HD, et al
J Gastroenterol Hepatol. 2006 Jan;21(1):319-326.
Abstract

Pilot study of interferon-alpha-ribavirin-interleukin-2 for treatment of nonresponder patients with severe
liver disease infected by hepatitis C virus genotype 1.
Alric L, Thebault S, Peron JM, et al
J Viral Hepat. 2006 Feb;13(2):139-44.
Abstract

Serious ophthalmic pathology compromising vision in HCV/HIV co-infected patients
treated withpeginterferon alpha-2b and ribavirin.
Farel C, Suzman DL, McLaughlin M, et al
AIDS. 2004 Sep 3;18(13):1805-9.
Abstract

Sudden hearing loss in patients with chronic hepatitis C treated with pegylated
interferon/ribavirin.
Formann E, Stauber R, Denk DM, et al.
Am J Gastroenterol. 2004 May;99(5):873-7.
Abstract

Ribavirin/interferon-alpha sequential treatment of recurrent hepatitis C after liver
transplantation.
Giostra E, Kullak-Ublick GA, Keller W, et al
Transpl Int. 2004 Apr 2
Abstract

Interferon Alpha-2b/Ribavirin

     Journal Papers, Abstracts, and Commentaries

Lack of rapid virological response predicts interferon-alpha2b/ribavirin therapy failure in HCV
genotype 2 patients: a single-centre study.
Rumi MG, Aghemo A, D'Ambrosio R. et al
Antivir Ther. 2007;12(7):1033-40.
Abstract

Interferon alfa-2b and ribavirin: new indication. In children: more risks than in adults.
[No authors listed
Prescrire Int. 2007 Apr;16(88):63-5.
Abstract

A study of low dose peginterferon alpha-2b with ribavirin for the initial treatment of chronic
hepatitis C.
Krawitt EL, Gordon SR, Grace ND, et al
Am J Gastroenterol. 2006 Jun;101(6):1268-73.
Abstract

FULL-TEXT ARTICLE
Triple therapy of interferon and ribavirin with zinc supplementation for patients with
chronic hepatitis C: A randomized controlled clinical trial.
Suzuki H, Takagi H, Sohara N, Kanda D, et al
World J Gastroenterol. 2006 Feb 28;12(8):1265-9.
Paper

FULL-TEXT PDF ARTICLE
The spectrum of thyroid dysfunction in an Australian hepatitis C population treated with
combination Interferon-alpha-2beta and Ribavirin.
Tran HA, Jones TL, Batey RG.
BMC Endocr Disord. 2005 Oct 12;5(1):8
Paper

Treatment of HCV infection with interferon alpha-2b and ribavirin in a patient with X-linked
lymphoproliferative syndrome.
Strnad-Trojan N, Linde R, Reichenbach J,et al
Eur J Pediatr. 2006 Feb 4;:1-3
Abstract

High-dose interferon-alpha2b induction therapy in combination with ribavirin for treatment of chronic
hepatitis C in patients with non-response or relapse after interferon-alpha monotherapy.
Hass HG, Kreysel C, Fischinger J. et al ;
World J Gastroenterol. 2005 Sep 14;11(34):5342-6.
Abstract

FULL-TEXT ARTICLE
Acute sensorineural hearing loss associated with peginterferon and ribavirin combination therapy
during hepatitis C treatment: Outcome after resumption of therapy.
Wong VK, Cheong-Lee C, Ford JA, Yoshida EM.
World J Gastroenterol. 2005 Sep 14;11(34):5392-3.
Paper

Comparison of a 6-month course peginterferon alpha-2b plus ribavirin and interferon alpha-2b
plus ribavirin in treating Chinese patients with chronic hepatitis C in Taiwan.
Lee SD, Yu ML, Cheng PN, Lai MY, et al
J Viral Hepat. 2005 May;12(3):283-91.
Abstract

Exacerbation of Psoriasis due to Peginterferon alpha-2b plus Ribavirin Treatment of Chronic
Active Hepatitis C.
Kartal ED, Colak H, Ozgunes I, Usluer G.et al
Chemotherapy. 2005 May 9;51(2-3):167-169
Abstract

Peginterferon {alpha}-2b and ribavirin therapy in chronic hepatitis C genotype 4: impact
of treatment duration and viral kinetics on sustained virological response.
Kamal SM, El Tawil AA, Nakano T
Gut. 2005 Jun;54(6):858-66
Abstract

Case Report: Hemolytic Anemia During Pegylated IFN-alpha2b Plus Ribavirin Treatment for
Chronic Hepatitis C: Ribavirin Is Not Always the Culprit.
Gentile I, Viola C, Reynaud L, et al
J Interferon Cytokine Res. 2005 May;25(5):283-5
Abstract

The effect of adherence to therapy on sustained response in daily or three times a week "
interferon alpha-2b plus ribavirin treatment of naive and nonresponder chronic hepatitis
C patients.
Raptopoulou M, Tsantoulas D, Vafiadi I, et al
J Viral Hepat. 2005 Jan;12(1):91-5
Abstract

Follow-up of Adverse Drug Reactions from Peginterferon alfa-2b-Ribavirin Therapy.
Bagheri H, Fouladi A, Barange K, et al
Pharmacotherapy. 2004 Nov;24(11):1546-1553.
Abstract

Suicidal ideation during interferon-alpha2b and ribavirin treatment of patients with chronic
hepatitis C.
Dieperink E, Ho SB, Tetrick L, et al
Gen Hosp Psychiatry. 2004 May-Jun;26(3):237-4
Abstract

Treatment of Chronic Hepatitis C in HIV-Infected Patients with Interferon alpha-2b Plus
Ribavirin.
Perez-Olmeda M, Soriano V, Asensi V,et al.
AIDS Res Hum Retroviruses. 2003 Dec;19(12):1083-1089
Abstract

First-line therapy with daily versus thrice-weekly interferon alfa-2b plus ribavirin for chronic
hepatitis C.
Reiser M, Buggisch P, Grossmann J, et al
Eur J Gastroenterol Hepatol. 2003 Dec;15(12):1299-304
Abstract

Early prediction of nonresponders to treatment with interferon alpha-2b and ribavirin in
patients with
chronic hepatitis C.
Liu LW, Tomlinson G, Mazzulli T, et al.
Can J Gastroenterol. 2003 Aug;17(8):483-7.
Abstract

Effects of alpha interferon induction plus ribavirin with or without amantadine in the treatment of
interferon non-responsive chronic hepatitis C: a randomised trial.
Adinolfi LE, Utili R, Tonziello A, Ruggiero G., et al.
Gut 2003 May;52(5):701-5
Abstract

A Prospective Study of Neuropsychiatric Symptoms Associated With Interferon-alpha-2b and
Ribavirin Therapy for Patients With Chronic Hepatitis C.
Thuras P, et al
Psychosomatics 2003 Mar-Apr;44(2):104-12
Abstract

Cost effectiveness of peginterferon alpha-2b plus ribavirin versus interferon alpha-2b plus
ribavirin for initial treatment of chronic hepatitis C.
Siebert U, Sroczynski G, Rossol S, et al.
Gut 2003 Mar;52(3):425-32
Abstract

Interferon-alpha 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation:
a randomized study.
Samuel D, Bizollon T, Feray C, Roche B, et al.
Gastroenterology 2003 Mar;124(3):642-50
Abstract

A randomized 4-arm multicenter study of interferon alfa-2b plus ribavirin in the treatment of
patients with chronic hepatitis C relapsing after interferon monotherapy.
Saracco G, Olivero A, Ciancio A, et al.
Hepatology 2002 Oct;36(4 Pt 1):959-66
Abstract
FULL-TEXT ARTICLE
Treatment of acute hepatitis C virus infection with interferon-alpha 2b and ribavirin:
Case report and review of the literature.

Leblebicioglu H, Bayirli D, Esen S, et al
Ann Clin Microbiol Antimicrob 2002 Oct 14;1(1):3
Paper

Emotional distress during interferon-alpha-2B and ribavirin treatment of chronic hepatitis C.
Fontana RJ, Schwartz SM, Gebremariam A, et al.
Psychosomatics 2002 Sep-Oct;43(5):378-85
Abstract

Interferon-alpha-2b and ribavirin for retreatment of chronic hepatitis C.
Dettmer RM, Reinus JF, Clain DJ,et al.
Hepatogastroenterology 2002 May-Jun;49(45):758-63
Abstract

Interferon-alpha-2b plus ribavirin: a review of its use in the management of chronic
hepatitis C.
Scott LJ, Perry CM.
Drugs 2002;62(3):507-56
Abstract

Long-term combination of interferon alfa-2b and ribavirin for hepatitis C recurrence in liver
transplant patients.
Kornberg A, Hommann M, Tannapfel A, et al.
Am J Transplant 2001 Nov;1(4):350-5
Abstract

Combination Interferon alfa-2b/ribavirin therapy for the treatment of epatitis C: nursing
implications.
Birkel A, Caldwell L, Stafford-Fox V, et al.
Gastroenterol Nurs 2000 Mar-Apr;23(2):55-62
Abstract

Interferon alfa-2b plus ribavirin for chronic hepatitis C patients who have
not responded to interferon monotherapy.
Lo Iacono O, Castro A, Diago M, et al.
Aliment Pharmacol Ther 2000 Apr;14(4):463-9
Abstract

Interferon Alpha-2b/Ribavirin

   Journal Papers, Abstracts, and Commentaries

FULL-TEXT PDF ARTICLE
Efficacy and safety of combination therapy of natural human interferon beta and ribavirin in chronic
hepatitis C patients with genotype 2 and high virus load.
Arase Y, Suzuki F, Akuta N, et al
Intern Med. 2010;49(11):965-70
Paper

Triple therapy of initial high-dose interferon with ribavirin and amantadine for patients
with chronic hepatitis C.
Uyama H, Nakamura H, Hayashi E, et al
Hepatol Res. 2007 May;37(5):325-30.
Abstract

Neurocognitive changes in patients with hepatitis C receiving interferon alfa-2b
and ribavirin.
Kraus M, Schafer A, Wissmann S, et al
Clin Pharmacol Ther. 2005 Jan;77(1):90-100
Abstract

Effect of interferon and ribavirin combined with amantadine in interferon and ribavirin
non-responder patients with chronic hepatitis C (genotype 1).
Oguz D, Cicek B, Filik L, Odemis B, et al
World J Gastroenterol. 2005 Jan 28;11(4):580-
Abstract

Triple combination of interferon alpha-2b, ribavirin, and amantadine for treatment of chronic
hepatitis C.
Younossi ZM, Mullen KD, Hodnick S
J Clin Gastroenterol 2003 May-Jun;36(5):427-30
Abstract

Histamine Dihydrochloride and Interferon-Alpha-2b

     Journal Papers, Abstracts, and Commentaries

A multicentre, randomized study to evaluate the safety and efficacy of
histamine dihydrochloride and interferon-alpha-2b for the treatment of chronic hepatitis C.
Lurie Y, Nevens F, Aprosina ZG, et al.
J Viral Hepat 2002 Sep;9(5):346-353
Abstract

Interferon Beta: General Reports

    Journal Papers, Abstracts, and Commentaries

FULL TEXT PDF ARTICLE
The efficacy of short-term interferon-beta therapy for chronic hepatitis C patients with
low virus load.
Kawamura Y, Arase Y, Ikeda K, et al
Intern Med. 2008;47(5):355-60.
Paper

FULL-TEXT PDF ARTICLE
Efficacy and safety of combination therapy of natural human interferon beta and ribavirin in
chronic hepatitis C patients with genotype 1b and high virus load.
Arase Y, Suzuki F, Akuta N, et a
Intern Med. 2010;49(11):957-63
Paper

Safety of interferon beta treatment for chronic HCV hepatitis.
World J Gastroenterol. 2004 Jan;10(1):12-6
Abstract

    Conference Reports, Abstracts, and Posters

Infection Rates in HIV/HCV and HCV Patients Treated with Interferon Are Similar and not
Related to Neutropenia
(13 CROI)
Abstract

Albinterferon-alfa 2b

   Journal Papers, Abstracts, and Commentaries

Albinterferon-alfa 2b: a new treatment option for hepatitis C.
Flisiak R, Flisiak I.
Expert Opin Biol Ther. 2010 Sep 9
Abstracts

HCV Drugs Main Page Main New/Newsworthy Home Page

Interferon Therapy- HCV Indications

Medical Advocates HCV Infection/Disease
	Interferon Therapy
	General Reports Consensus Interferon Interferon Alpha Recombinant Interferon-Alpha Interferon Alpha/RBV Interferon Alpha-2a Interferon Alpha-2b Interferon Alpha-2a/RBV Interferon Alpha-2b/RBV Interferon Alpha-2b/RBV/AMT Interferon Beta Albinterferon-alfa 2b	Peg Interferon-Alfa-2a Peg Interferon-Alfa-2b